PRRT2

Across TCGA pan-cancer cohorts, PRRT2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PRRT2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRRT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRRT2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM are the cancer types where PRRT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.544	0.221	.005	7	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PRRT2–GBM (DFS)

Open the GBM breakdown →